Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must agree to the study protocol and provide written informed consent~2. Outpatients ≥ 20 years of age, male or female~3. Patients with secondary functional MR (stage B and C) and LV dysfunction~   * Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent~  * Normal mitral valve leaflets and chords~  * Regional or global wall motion abnormalities with mild or severe tethering of leaflet~  * ERO \> 0.10 cm2~  * 25% \< LV ejection fraction \< 50%~4. Dyspnea of NYHA functional class II or III~5. Patients must be on stable, optimized dose of an ACE inhibitors or ARBs for at least 4 weeks prior to study entry~Exclusion Criteria:~1. History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drug~2. Known history of angioedema~3. Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles~4. Current acute decompensated heart failure or dyspnea of NYHA functional class IV~5. Medical history of hospitalization within 6 weeks~6. Symptomatic hypotension and/or a SBP \< 100 mmHg at screening~7. Estimated GFR \< 30 mL/min/1.73m2~8. Serum potassium \> 5 mmol/L at screening~9. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt~10. Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months~11. Planned coronary revascularization or mitral valve intervention within 1 year~12. Heart transplantation or implantation of cardiac resynchronization therapy~13. History of severe pulmonary disease~14. Significant aortic valve disease~15. Primary aldosteronism~16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method~17. Pregnant or nursing (lactating) women~18. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 (Type: EXPERIMENTAL): LCZ696 for 12 months
- Valsartan (Type: ACTIVE_COMPARATOR): Valsartan for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).